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Myocardial Infarction (MI) is the most common cardiovascular disease. An average-sized
MI causes the loss of up to 1 billion cardiomyocytes and the adult heart lacks the capacity
to replace them. Although post-MI treatment has dramatically improved survival rates
over the last few decades, more than 20% of patients affected by MI will subsequently
develop heart failure (HF), an incurable condition where the contracting myocardium
is transformed into an akinetic, fibrotic scar, unable to meet the body’s need for
blood supply. Excessive inflammation and persistent immune auto-reactivity have been
suggested to contribute to post-MI tissue damage and exacerbate HF development.
Two newly emerging fields of biomedical research, immunomodulatory therapies and
cardiac bioengineering, provide potential options to target the causative mechanisms
underlying HF development. Combining these two fields to develop biomaterials for
delivery of immunomodulatory bioactive molecules holds great promise for HF therapy.
Specifically, minimally invasive delivery of injectable hydrogels, loaded with bioactive
factors with angiogenic, proliferative, anti-apoptotic and immunomodulatory functions,
is a promising route for influencing the cascade of immune events post-MI, preventing
adverse left ventricular remodeling, and offering protection from early inflammation to
fibrosis. Here we provide an updated overview on the main injectable hydrogel systems
and bioactive factors that have been tested in animal models with promising results and
discuss the challenges to be addressed for accelerating the development of these novel
therapeutic strategies.
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IMMUNE FEATURES OF CARDIOVASCULAR DISEASE AND
HEART FAILURE
Cardiovascular diseases (CVDs) is the leading cause of death worldwide (1). In Europe only, CVDs
claim more than 4 million lives each year, accounting for 49% of death among women and 40%
among men (2). Myocardial infarction (MI) is the most common CVD (1). MI occurs when the
supply of freshly oxygenated blood to the left ventricle is blocked as a result of a prolonged coronary
artery occlusion. This occlusion and the resulting ischemic damage cause the loss of up to 1 billion
cardiomyocytes (CMs) (3). Given the limited intrinsic regenerative capacity of the heart, surviving
cardiomyocytes increase in size more than in number (4) and a non-contractile fibrous scar is
formed to avoid fatal cardiac rupture.
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Although cardiomyocyte death initiates an inflammatory
response that is essential for early removal of necrotic
debris and scar formation, persistent inflammation can
cause immune-mediated tissue damage (5). Anti-cardiac
autoreactivity of the adaptive immune system progressively
contributes to structural remodeling and functional
decline (6–8), inducing morphological changes such as left
ventricular (LV) remodeling that compromises the function
and pumping capacity of the heart. These cumulative
immune responses lead to the progressive spiral toward
heart failure (HF) (9), where the heart is incapable of
generating sufficient cardiac output to meet the demands of
the body.
HF has a poor prognosis and no effective treatment is
available to date (10), the disease is associated with poor
quality of life, high healthcare costs, and a high mortality
rate (11, 12). Current treatments comprise pharmacotherapy,
medical devices such as ventricular assist devices, and heart
transplant. The first two strategies optimize the function of the
remaining viable cardiomyocytes, and although successful in
saving and improving quality of life they do not address the
underlying causes of cell loss and restore lost cardiac tissue,
and therefore cannot effectively manage the progression to HF.
Heart transplantation remains the only effective treatment to
restore fully functioning cardiac tissue (13, 14), but the limited
amount of available donors and complications from immune
rejection make it impractical for the number of people affected
by HF (15). As a result, there is a pressing need for effective
methods to regenerate damaged myocardium and prevent
adverse remodeling.
Here we discuss the status quo of tissue engineering
approaches to improve cardiac regeneration after MI, and
how intended or fortuitous immunological properties of
biomaterials may underlie their beneficial effects. We first
focus on injectable in situ gelling systems and the relative
material design criteria that need to be considered for cardiac
repair applications. We then present an overview of the main
bioactive molecules with pro-angiogenic, anti-apoptotic and
anti-inflammatory properties, delivered in vivo as single or
combined factors in animal models of MI. Finally, we discuss
some of the challenges when considering a clinical translation of
these strategies.
HYDROGELS AS A NOVEL THERAPEUTIC
APPROACH AFTER MI
Tissue engineering and regenerative medicine have recently
emerged as a prospective option for MI and HF treatment.
The availability of engineered or regenerated cardiac tissue to
supplant donated hearts would be a significant step forward
in improving patient prognosis and advance treatments for
MI. Biomaterial-based strategies are being developed to tackle
cardiac regeneration post-MI, strengthened by the conclusion
that 95–99% of therapeutic stem cells delivered to the infarcted
heart are lost within the first 24 h (16–18). In addition to
providing mechanical support for the damaged myocardial
wall, tissue engineering strategies have the potential to enhance
cell survival and cell retention, reducing immediate cell loss
due to mechanical washout and promoting integration into
the host tissue. Biomaterials not only to address the issue
of cell engraftment but also aid in the clinical translation of
therapies based on bioactive molecules, systemic administration
of which is hindered by their short in vivo half-life, the
need for repeated injections and high cost of treatment. By
stably delivering bioactive molecules to the area of damage,
biomaterials have the potential to counteract the morphological
changes leading to HF by promoting angiogenesis and
cell survival.
The two main strategies currently implemented for cardiac
tissue engineering are cardiac patches or scaffolds and in situ
gelling systems. Engineered scaffolds or patches are solid porous
polymeric matrices which may have cells and/or bioactive
molecules attached to them (19). These approaches are limited
by the invasive procedure by which they are applied, as they
require invasive surgeries for implantation and is not an
option for patients with advanced HF, due to comorbidities
that exclude them from undergoing surgery. In the 1990s,
a therapeutic strategy involved ventricular restraints such as
polymeric meshes enfolding the heart or sutured to its surface.
Several studies have shown that they are effective in reducing
infarct expansion by mechanically stabilizing the heart, limiting
long-term changes in the LV geometry in large animal models
(20–22) with minimal options for clinical translation (23),
leaving cardiac patches and in situ gelling systems as the
two main approaches currently investigated for cardiac tissue
engineering (24).
In the gel category, hydrogels have received considerable
attention as “water-swollen polymer networks” (23) that
have a high percentage of water content similar to human
tissue (25). They can be prepared from polymers of either
natural or synthetic origin and they are able to absorb
a considerable amount of water or biofluids, resulting in
swelling with maintenance of their shape (26). As injectable
fluid, they represent a minimally invasive approach (27)
used for the localized delivery of bioactive molecules to
target sites, allowing for well-controlled release kinetics
and increasing the functional half-life of cargo molecules.
As a delivery vehicle, hydrogels can also be used for
“combination strategies,” simultaneously encapsulating cells and
bioactive molecules.
DESIGN OF INJECTABLE BIOMATERIALS
FOR CARDIAC TISSUE ENGINEERING
When designing any biomaterial for tissue engineering
application, important considerations include the function
and composition of the target tissue. Biomaterials should
have biological and physical properties mimicking those of
the target tissue and should be able to degrade upon tissue
regeneration. Materials for myocardial tissue engineering
should ideally be designed to offer mechanical support
to the infarcted myocardium, while not interfering with
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synchronization and myocardial geometry. In this respect,
an injectable/in situ polymerizable material is advantageous
over a patch because upon injection it can uniformly disperse
in the myocardial wall remaining anchored by interstitial
placement (28).
Injectability and Delivery Methods
A hydrogel that can pass through a fine gauge needle (27G)
can be safely administered through intramyocardial injection
with a minimally invasive approach (29). Injectability is achieved
when the gelation of the hydrogel is either initiated but not
completed in the needle or initiated and completed after delivery
at the target site. Importantly, polymerization time should be in
the order of tens of minutes or shorter so that to ensure the
hydrogel is successfully localized and not washed out with the
contraction of the heart (30). In the context of cardiac repair,
injectable hydrogels represent a minimally invasive approach,
decreasing the damage incurred to the targeted and surrounding
tissue during delivery (27). The ideal method of delivery
providing a quick path to clinical translation would use current
catheter technology, but although highly patient-compliant, it
poses some challenges for the designing the material which
must be maintained in liquid form for the duration of the
injection procedure (up to 1 h) and then solidify into a hydrogel
once within the myocardial wall. A thermo-responsive hydrogel
delivered through a cooled injection system could overcome
this challenge.
There are three main methods for the clinical delivery of
injectable hydrogel therapies, each with its advantages and
limitations. The first is intracoronary injection with a catheter
via an inflated percutaneous transluminal coronary angioplasty
(PTCA) balloon. This approach is unique as it exploits leaky
vessels in the damaged region for the delivery, instead of a
puncture injection, and it utilizes currently available technology
without the need for additional training. However, it requires
special material design and the volume of delivered material
cannot be controlled well due to passive leakage from the target
vessel (27). A second approach is direct epicardial injection
into the heart; advantages of this method include an accurate
location control while a drawback is that endoscopic application
or open chest access required for the administration are invasive
procedures. Lastly, another less invasive approach is trans-
endocardial injection via catheter combined with imagining
technology such as NOGA R© (31). However, this method requires
specialized training for both the injection catheter and the
imaging modality so is not currently routinely performed (27).
Stiffness and Mechanical Support
Considerations regarding the mechanical requirements of a
biomaterial must take into account the in vivo model where it
will be tested, since the forces exerted by a human heart will
vastly differ from those of a small rodent. Physiologically, the
stiffness of the human myocardium ranges from 20 kPa at end-
diastole to 500 kPa at the end-systole (32, 33), whereas that
of the rat myocardium goes from 0.1 to 140 kPa (33). As the
collagenous scar forms, the infarcted myocardium undergoes a
time-dependent stiffness change becoming less and less flexible.
As measured by atomic force microscopy (AFM), the baseline
elastic modulus, which measures the ability of a material to resist
deformation, of non-infarcted rat myocardium is 18± 2 kPa (34).
In the first 24 h after MI the stiffness of infarcted myocardium
is relatively soft (4–17 kPa) (35), whereas in the 2 weeks post-
MI, significant fibrosis is formed resulting in a threefold increase
in the elastic modulus (55 ± 15 kPa) (34). It is known that
the physical characteristics of the microenvironment have an
effect on the survival and differentiation of the engrafted cells
(35). Therefore, the response to cell and material implantation
will vary with the stiffness of the infarcted tissue, which in turn
depends on the time post-infarction (30). A material envisioned
to provide long-termmechanical support should have a high-end
stiffness, matching the one of the native myocardium, whereas a
material designed for the injection and the delivery of cells and/or
bioactive factors should have a low stiffness, as long as it is able to
withstand the contraction/dilation of the heart.
Application Time Post-MI
Since recent and old infarcts have their distinct features and
challenges, an important consideration for material design is
the time post-MI at which the material is injected. Depending
on injury stage and extent of remodeling, the status of MI
is categorized as acute (1–7 days), sub-acute (1–3 weeks) or
chronic (>1month). Application of therapeutic agents in chronic
models has so far shown little success in improving regeneration,
and regenerative therapy in chronic MI remains a challenge.
While acute MI involves early ventricular damage, chronic
MI changes the ventricular shape, causing a time-dependent
dilation, and LV hypertrophy (36). Delivering therapeutic factors
shortly after an MI might protect the remote myocardium,
minimize scar formation and ultimately attenuate pathological
remodeling. However, delivering cells or bioactive molecules too
soon risks exposing them to a hostile ischemic and inflammatory
environment. The time of injection in in vivo studies ranges from
immediate (37–40) to 1 week (41, 42) to 2 months post-MI (37).
The most common approach in animal models is an immediate
injection, which unfortunately does not accurately mimic the
clinical situation because patients would not receive a therapy
for a minimum of several hours, if not days, post-MI. Hence,
studies investigating the effect of biomaterial injections at later
time points such as 2 months are valuable to test the possibility
to avoid scar expansion and LV dilation in patients that did not
receive an earlier treatment (27). Many studies have looked at
the importance of application timing, showing how it underpins
the benefit seen in the long term. For example, in a murine
model of MI, intramyocardial injection of a collagen matrix is
only effective at preventing negative ventricular remodeling and
long-term decline of cardiac function if administered 3 h after
MI rather than 1 week or 2 weeks after [38]. On the other
hand, a study investigating the effect of an injectable alginate
implant showed beneficial effects both in recent (<7 days) and
old (60 days) infarctions, indicating how other concomitant
factors (animal model used, one vs. multiple injections, sites of
the injections) could contribute to the observed outcome (37).
Timing of therapy may be particularly crucial if an
immunomodulatory component is included. The immune
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response after an MI follows a time-dependent course with
distinct but overlapping phases and the outcome of a specific
immunomodulatory treatment will be highly dependent on
the prevailing inflammatory environment (43), as depicted
in Figure 1. During the early inflammatory phase, pro-
inflammatory monocytes and macrophages together with
neutrophils infiltrate the injured area, clearing the necrotic
cardiomyocytes (44). Here, the target for a biomaterial-based
strategy would be to promote cardiomyocyte survival and
attenuate leukocytes and acute inflammation by supporting
efficient resolution of inflammation. The second, proliferative,
phase is characterized by fibroblasts and endothelial cell
proliferation, ECM deposition and formation a vascularized
granulation tissue, accompanied by recruitment of lymphocytes,
angiogenesis, and myofibroblasts differentiation (44). At this
stage, a biomaterial therapy should aim at regulating macrophage
phenotype and function, controlling fibroblast activity and
matrix remodeling and promoting angiogenesis. During the
final maturation phase, myofibroblast activation recedes and a
mature collagen-rich scar is formed which is mostly devoid of
cardiomyocytes, hence non-contractile (44). At this point, the
goal for any strategy is the replacement of lost cardiomyocytes,
potentially delivering cells through a biomaterial approach. In
parallel, immunomodulatory strategies may need to forego local
factor delivery and aim at targeting ongoing systemic immune
activation (8).
Responsiveness to External Stimuli
An advantage of using injectable delivery systems is the
opportunity to tailor polymerization and drug release
characteristics to respond to clinically relevant stimuli present
in the target tissue microenvironment. Stimulus-responsive
“smart” polymers (45) have the unique property of undergoing
gelation or cargo-release in response to environmental stimuli
(46). Stimuli that have been exploited for regenerative medicine
applications in vitro and in vivo, including cardiac repair, include
temperature (47, 48), pH (49, 50), light (28), and enzymes such as
metalloproteinases (51).
Temperature-responsive and biodegradable hydrogels are
usually in the form of an injectable solution at room temperature,
becoming a biodegradable solid at 37◦C. These are advantageous
for cardiac repair since they undergo a gelation process under
physiological conditions that allow them to support cell viability
and bioactivity of the encapsulated molecules while avoiding
damage to the adjacent tissue (52). Another stimulus that can
be used to trigger hydrogel polymerization is pH, particularly
relevant in the context of myocardial infarction where the pH
drops from the physiological value of 7.4 to 6.5–6.8 due to
the switch from aerobic to anaerobic metabolism (53). An
acidic microenvironment such as the ischemic myocardium is
also an endogenous danger signal alerting the innate immune
system and contributing to inflammation (54). Specifically, the
acidification of the environment cause macrophages to increase
the secretion of the pro-inflammatory cytokines IL-1β and IL-18
(54). Since IL-1 antagonist therapies are being developed for the
treatment of MI (55–57), the use of a pH-sensitive drug delivery
hydrogel system in a context where IL-1 levels are elevated
would potentially be an effective and novel anti-inflammatory
therapeutic strategy.
Bioactivity of the Released Molecules
Another important parameter to consider when designing
injectable hydrogels is their ability to protect bioactivity of
their biological cargo. In this respect, studies testing these
systems in vivo should compare the bioactivity of the native
factor with the released factor. In general, growth factors and
FIGURE 1 | Representation of biomaterial strategies to tackle different post-MI phases.
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cytokines are unstable molecules with short in vivo half-lives.
In the inflammatory and acidic environment of the infarcted
myocardium, the bioactivity and stability of these molecules is
further decreased due to the abundance of proteases and high
oxidative stress (58). Hence, hydrogels can act as reservoirs
for the sustained and localized delivery of these important
regulators under protease-rich conditions. Pioneering work by
Langer and Folkman showed that molecules encapsulated in
polymer matrixes can display a sustained released for up to 100
days (59). Usually, molecules released from hydrogels exhibit
an initial “burst release,” followed by a sustained release profile
with slower release rate; however, release kinetics are unique to
every biomaterial-cargo combination and must be determined in
each case.
A novel class of injectable hydrogels that present a promising
option in regard to maintain the bioactivity of the cargo are
coacervate hydrogels (60). They are formed by polyelectrolytes
of opposing charges mixed together to form droplets held by
electrostatic forces (61). Once encapsulated within the coacervate
phase, unstable proteins or drugs are separated and protected
from the surrounding environment, thereby preserving their
bioactivity (60). Moreover, due to their size, coacervates can be
applied via very fine gauge needles, important for minimizing
damage associated with injection (60).
Biocompatibility and Immunomodulation
Biocompatibility is defined as “the ability of a material to perform
with an appropriate host response in a specific application”
(62). The concept of biocompatibility is a characteristic of the
material-host interaction more than a material property (63).
Specifically, the material should not initiate a substantial foreign
body response in vivo. This does not preclude the activation of an
immune response but shifts the focus on controlling the type and
the magnitude of the response in order to prevent further cardiac
damage (29). In the past, emphasis was put on minimizing
the inflammatory response to biomaterials altogether. However,
recent studies demonstrate that the endogenous healing and
regeneration processes can be supported by fine-tuning the
balance between pro- and anti-inflammatory response (64).
As a relevant example, macrophages are highly dynamic and
responsive to their micro-environment, and biomaterials have
the potential to alter the macrophage response and their
polarization toward a regenerative rather than an inflammatory
phenotype after MI. The effect of biomaterials on macrophage
polarization has been investigated by several groups, focusing
on the responses to cellular or acellular grafts (65), natural (66)
or synthetic (67) origin and different fibers and porous sizes
(68, 69). Badylak et al. compared a natural-derived scaffold made
of porcine small intestinal submucosa (SIS) with its crosslinked
version, known as CuffPatch (CDI-SIS) (66). The SIS patch
induced a strong mononuclear response at 1-, 2-, and 4-weeks
post implantation, as determined by CD163+ macrophages.
On the other hand, the crosslinked CDI-SIS patch elicited the
recruitment of an equal proportion of CD80+ pro-inflammatory
and CD163+ anti-inflammatory macrophages at 1- and 2-
weeks, with the anti-inflammatory population predominant in
later time points and observed at the border zone rather than
infiltrating the scar. Physical properties such as fiber diameter
and pores size are also able to influence macrophages: larger
fibers and pore size of different types of scaffolds induce the
differentiation of anti-inflammatory macrophages, characterized
by an increased production of wound-healing mediators such as
Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast
Growth Factor (bFGF) and more potency in promoting capillary
formation in vitro (68, 69). This illustrates how small changes in
material properties can have significant effects on the immune
response elicited by the material and how the impact of the
biomaterial on the macrophage population may significantly
contribute to the overall success of a biomaterial strategy.
HYDROGEL-BASED APPLICATIONS IN
CARDIAC TISSUE ENGINEERING
Injectable hydrogels without addition of cells or molecular
therapeutics have elicited functional improvements and
prevention of left ventricular dilation in small and large animal
models. However, the combination of injectable strategies with
the delivery of growth factors, cytokines or other bioactive
molecules shows great promise as a therapeutic approach, as
hydrogels can help overcome the challenges associated with high
diffusion rates and their half-life in vivo as discussed above (23).
Injectable Hydrogels for Mechanical
Support
Injectable hydrogels can be used as a bulking agent after
MI, providing mechanical support to the infarcted heart, and
preventing ventricular remodeling by attentuating wall stress
(23, 70). This has not only been shown in small and large animal
models but also confirmed by computational models (71–73).
One of the earliest materials used for cardiac repair was fibrin,
a biodegradable protein involved in the coagulation cascade
(74). The field of acellular injectable materials was pioneered by
Christman et al. who explored the effects of fibrin glue as post-MI
bulking agent (75, 76), showing its ability to recruit endothelial
cells, and to increase capillary density, probably due to the fact
that fibrin contains binding domains for angiogenic factors, such
as FGF (77). An ECM-derived hydrogel, specifically from pig
heart ventricles, has also been investigated as an acellular bulking
agent, following percutaneous delivery via trans-endocardial
injection in a rat model of MI (78). Results showed a decrease
in the loss of endogenous cardiomyocytes and a preserved
cardiac function and were later further confirmed in pig models
(79), demonstrating that providing cardiac-specific cues to the
injured myocardium via decellularized cardiac ECM hydrogels
is a promising strategy to reduce infarct size and promote tissue
formation (23).
Hydrogels made of alginate, a naturally occurring linear
polysaccharide found in brown seaweed algae, are of high interest
for tissue engineering applications, due to their biocompatibility,
non-thrombogenic nature and resemblance to ECM (80, 81).
Alginate hydrogel injection has shown beneficial results in
rat and porcine models of MI (37, 82) although, unlike
fibrin, alginate must be modified with adhesive peptides to
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facilitate cell binding (83). Leor et al. tested the effects of
intracoronary injection of alginate hydrogel in a healthy swine
heart, with no evidence of biomaterial deposition, necrosis and
inflammation at the injection site (82). However, being a material
of natural origin, there is a risk of contaminants, including
mold, yeast and bacteria, with the latter contributing to the
presence of endotoxins, mitogens and pyrogens (84). Since pro-
inflammatory cytokines play a role in the pathophysiology of HF
(85), these contaminants must be eliminated from biomedical
alginates for cardiac applications. Hence, the production of
alginate hydrogels for clinical use is strictly regulated by
several agencies worldwide (84). Recently, injections of a
commercially available calcium alginate hydrogel (Algisyl-
LVRTM) were evaluated for their ability to reduce LV wall stress
in HF patients with an ejection fraction (EF) <40% (72). Three
months after treatment, LV wall thickness increased by 20%
and end-systolic volume (ESV) decreased by 30%, showing
for the first time that an acellular alginate hydrogel might
be beneficial in the treatment of HF patients (72). Another
study (AUGMENT-HF trial) investigated direct injections of
alginate hydrogel in the myocardium of 113 patients; the material
was administered through left thoracotomy with multiple
intramyocardial injections and it was effective in improving
cardiac function in chronic HF patients (86).
Synthetic hydrogels have also been tested as acellular in
situ gelling systems. For example, a material consisting of α-
cyclodextrin (α-CD) and poly (ethylene glycol) (MPEG-PCL-
MPEG) triblock copolymer that can form a gel in situ has shown
functional LV improvement when injected in rodents models
(70, 87). Fujimoto et al. designed and tested a biodegradable
thermo-responsive hydrogel made of N-isopropylacrylamide
(NIPAAm), acrylic acid (AAc) and hydroxyethyl methacrylate-
poly(trimethylene carbonate) (HEMAPTMC)which formed a gel
at body temperature (48). Overall, this biodegradable material
improved cardiac function and preserved the thickness of the
ventricular wall compared with PBS injection in a rat model of
MI. Specifically, the hydrogel distributed in the anterior wall and
was infiltrated by macrophages and fibroblasts. This indicates
that the macrophage phagocytic and secretory activity leads to
a faster hydrolytic cleavage of the hydrogel in vivo rather than in
vitro (48). Hydrogels are usually degraded by hydrolysis and the
resulting small particles are phagocytized by macrophages at the
injection site. Macrophage infiltration is associated with a higher
expression of VEGF and bFGF around the newly formed vessels
and these locally secreted angiogenic factors might positively
influence tissue remodeling (48, 88).
INJECTABLE HYDROGELS FOR THE
DELIVERY OF BIOACTIVE FACTORS
Due to their critical role in controlling cellular functions and
orchestrating tissue regeneration, bioactive factors have received
growing interest for regenerative applications in cardiovascular
medicine. Many studies now highlight how the beneficial effects
derived from the administration of stem cells into the infarcted
myocardium are in fact due to the paracrine effects of secreted
factors, rather than from direct action of the cells (89–93). This
has been reviewed thoroughly elsewhere (94–96). Factors that
activate specific intracellular pathways linked to cardioprotection
include intermediates in the PI3K-Akt and MEK1/2-Erk1/2 pro-
survival kinase pathways (97). However, as discussed above
the therapeutic potential of these molecules is limited by their
high rate of diffusion, short biological half-life (98), low plasma
stability and low specificity to target organs (99). For example,
post-MI intraperitoneal administration of a cocktail of growth
factors in rats did not improve cardiac function, infarct size
or neovascularization (98) and a single intracoronary infusion
of FGF in patients did not significantly improve myocardial
function in a phase 1 clinical trial (100). Therefore, the successful
clinical translation of tissue reparative benefits of bioactive factor
depends on new formulation and/or delivery approaches (99).
In addition to providing mechanical support, hydrogels can
also serve as a water-rich matrix to encapsulate regenerative
factors, representing a promising option for post-MI treatment.
Bioactive factors loaded into hydrogels to test their ability
to locally modulate cardiac repair include angiogenic (VEGF,
FGF), anti-apoptotic (IGF-1, NRG-β), proliferative (SDF-1) and
immunomodulatory (IL-10, TIMP-3) molecules (Figure 2).
ANGIOGENIC FACTORS
Angiogenesis refers to the development of blood vessels from
a pre-existing vascular bed. Clinically, the objectives can be to
either block vessel formation to treat tumors or to stimulate
angiogenesis in states of insufficient blood flow such as the
ischemic heart disease (101). In the context of myocardial
infarction, angiogenic therapy may salvage the ischemic tissue,
especially in the early stages post-MI. Angiogenesis occurs
in the granulation tissue during the proliferative phase post-
MI. However, supporting neovascularization of the viable,
surrounding myocardium at the infarct border zone may
improve the process of tissue remodeling (102). Most studies
have focused on the regenerative potential of VEGF and FGF.
Localized and low-dose delivery of pro-angiogenic factors is
particularly important because, regardless of how efficient the
uptake, a considerable proportion of an angiogenic factor
injected into a vessel supplying the target tissue will spill into
the systemic circulation and expose non-target tissue to its
biologic effects (103, 104). This is highly relevant for VEGF
and its angiogenic effects because high doses of VEGF may
result in the unregulated formation of haemangiomas (105)
or vascular leakage that leads to oedema and nitric oxide-
dependent hypotension (106, 107). Thrombocytopenia and renal
toxicity are the most likely side effects of high doses of FGF
(108). Additionally, the immune system is not normally exposed
to high doses of these factors and can potentially develop
antibodies against them, leading to decreased administration
efficacy. Hence, the use of injectable hydrogels that allow a
sustained yet localized delivery of pro-angiogenic factors is a
promising option for post-MI treatment. Examples of injectable
biomaterials tested for the delivery of pro-angiogenic factors in
animal models are summarized in Table 1.
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FIGURE 2 | Schematic of the injectable hydrogel approach for cardiac repair. Injectable hydrogels of either natural or synthetic origin can be loaded with bioactive
factors with anti-apoptotic, pro-angiogenic, anti-inflammatory, and immunomodulatory actions. The encapsulated factors are released over time, inducing formation of
new blood vessels, modulation of inflammation and post-MI immune response and cardiomyocytes survival. This eventually results in reduction of left ventricular
remodeling and improved overall cardiac function.
Vascular Endothelial Growth Factor (VEGF)
VEGFs are a family of glycoproteins of which VEGF-A (also
called VEGF-1) is the most extensively studied. Other members
of the family, which shares structural homology, are VEGF-C,
VEGF-B, VEGF-D and VEGF-E (117). Four species of VEGF-
A have been identified, differing in the number of amino
acids (VEGF121, VEGF165, VEGF189, and VEGF206). VEGF165
is the most abundant and predominant isoform of VEGF
in the heart. Since it is the major regulator of angiogenesis
in the heart, VEGF165 is also the most commonly used for
therapeutic angiogenesis post MI (117). The first study showing
its cardioprotective effects dates back to 1997 (118). Since
then, many approaches have been tested for VEGF delivery
to the ischemic heart, including gene therapy (119–121) and
intravenous and intracoronary administration (122, 123). The
clinical trial VIVA assessed the effects of intracoronary infusion
of recombinant human vascular endothelial growth factor
(rhVEGF) in patients with chronic myocardial ischemia, showing
a well-tolerated safety profile but no clinical improvements over
placebo by day 60 (124). However, by day 120, rhVEGF at high
dose led to significant improvement in angina and increasing
trends in the Exercise Treadmill Test (ETT). As in several
other trials (122, 125, 126), VIVA showed a dose-dependent
effect, highlighting once more the need for controlled and
sustained release.
Various types of hydrogels, either of natural or synthetic
origin, have been used for the delivery of VEGF. PEG-based
hydrogels provide several advantages for in vivo applications and
they have been extensively used in regenerative medicine
due to their high water content and the fact that they
can provide a three-dimensional environment similar to
soft tissue, allowing distribution of oxygen, nutrients and
metabolites (127–129). Recently, a biosynthetic injectable
hydrogel consisting of polyethene glycol and fibrinogen
(PEG-fibrinogen) loaded with VEGF and administered
by intramyocardial injection showed myocardial function
protection and improved vascularization in a rat MI
model (109).
The most common approach for the encapsulation of
a bioactive factors into an injectable hydrogel is simply by
mixing it with the polymer solution. However, previous studies
have shown that if angiogenic factors are immobilized on a
scaffold, their angiogenic potential is enhanced (130, 131).
Along these lines, a slightly different approach undertaken by
Wu et al. was to conjugate VEGF to a [Poly (δ-valerolactone)-
block-poly (ethylene glycol)-block-poly (δ-valerolactone)
(PVL-b-PEG-b-PVL)] instead of mixing it with the solution
(52). All the conditions (hydrogel alone, hydrogel mixed
with VEGF and hydrogel conjugated with VEGF) were
able to significantly attenuate adverse cardiac remodeling.
However, VEGF-conjugated hydrogels were better in boosting
angiogenesis, likely because the conjugation was able to extend
the biological activity of VEGF over the 42 days of biomaterial
degradation (52).
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TABLE 1 | Exemplar injectable biomaterials used for the in vivo delivery of pro-angiogenic growth factors in animal models of MI.
Biomaterial Growth
factor
Animal
model
Time of
administration
Outcome References
PEG-Fibrinogen VEGF Rat MI Immediately after MI Increased arterial density and improved cardiac
function
(109)
Thermo-responsive aliphatic
polyester
VEGF Rat MI 1 week post MI Improved angiogenesis and cardiac function with
smaller infarcts
(52)
Acidic gelatin hydrogel
microspheres
bFGF Canine MI 2 weeks post MI Improved collateral circulation near the coronary
occlusion
(110)
Acidic gelatin hydrogel
microspheres
bFGF Rat chronic
MI
4 weeks post MI Improved fractional shortening and
neovascularization. Increased collagen III/I ratio in
the fibrotic scar.
(111)
Acidic gelatin hydrogel
microspheres
bFGF Canine
chronic MI
4 weeks post MI Improved fractional shortening and capillary density (112)
Thermo-responsive chitosan bFGF Rat MI 1 week post MI Improved arteriogenesis, ventricular remodeling,
and cardiac function
(113)
Decellularised pericardial
ECM
bFGF Rat MI 1 week post MI Enhanced vascularization with newly formed
vasculature anastomosed with existing vessels
(114)
Dex-PCL-HEMA/PNIPAAm bFGF Rat MI Immediately after MI Reduced collagen, neoangiogenesis, and improved
cardiac function
(115)
(p[NIPAAm-co-PAA-co-BA]) bFGF Rat MI Immediately after MI Increased capillaries density. Improved cardiac
function with increased thickness of myocardial wall
(116)
These studies were mainly focused on material design
and characterization, and cardiac function was assessed by
echocardiography. Immunomodulatory effects of VEGF were
not tested. Importantly though, VEGF family factors not only
have a direct effect on endothelial cell survival and proliferation,
thus control new vessel formation and permeability, but also
recruit inflammatory and regenerative cells such as myeloid and
progenitor cells (102).
Basic Fibroblast Growth Factor (bFGF)
bFGF, a 16 kDa monomeric factor, is the most potent angiogenic
factor in the FGF family and it affects migration and proliferation
of endothelial cells, smooth muscle cells and fibroblasts (115).
However, its short half-life of only 3min and side effects induced
by high dose administration have hindered a robust clinical
translation so far. Since it was first demonstrated that FGF could
increase the number of capillaries and arterioles in the infarcted
dog heart (132), it has been widely used in animal models (47,
104) and clinical trials (100, 133, 134), showing treatment safety
but not yet demonstrating efficacy.
The first biomaterials used for local delivery were bFGF-
impregnated acidic gelatin hydrogel microspheres (AGHM),
improving collateral circulation to the infarcted area after
coronary occlusion in dogs significantly more than the free-form
bFGF (110). Gelatin microspheres were also used to deliver bFGF
in several hindlimb ischemia large animal models (135, 136).
These studies showed promising results, leading to progression
to clinical trials in patients with critical limb ischemia (137, 138).
Currently, the same approach is being tested in small (111)
and large animal models (112) of chronic MI. The improved
cardiac contractile function seen in these recent studies shows
how treatment with the sustained release of bFGF from gelatin
hydrogels could be clinically translated not only for peripheral
cardiovascular diseases but also for chronic MI.
In addition to gelatin microspheres, temperature-responsive
chitosan was used for the delivery of FGF post-MI by Wang
et al. (113). In this study, FGF was encapsulated in a thermo-
responsive chitosan hydrogel upon intra-myocardial injection.
This system significantly improved cardiac function compared
to injecting FGF alone in a rat model of chronic MI (hydrogel
injection 1-week post-MI) (113). bFGF also retains its bioactivity
when delivered through natural-derived hydrogels such as
decellularized pericardial ECM (114) or synthetic materials such
as (p[NIPAAm-co-PAA-co-BA]) (50). Recently, bFGF (139) has
shown overall amelioration of ischemic injury caused by MI in a
mouse model using coacervate hydrogels (60).
As an example of the immunomodulatory responses to
hydrogels, Garbern et al. designed a dual responsive polymer
made of poly(N-isopropylacrylamide-co-propyl acrylic acid-co-
butyl acrylate) (p[NIPAAm-co-PAA-co-BA]) which is a liquid at
pH 7.4 and 37◦C and forms a gel at pH 6.8 and 37◦C. They
hypothesized that the ability of this polymer to form a reversible
gel under the acidic conditions of the ischemic myocardium (pH
6.8) would allow it to first act as a depot system for the release
of bFGF, and secondly to promote polymer dissolution once the
tissue has returned to physiological pH (116). The system was
tested for its efficacy in vivo in a rat model of MI, showing
that it was able to provide a spatiotemporally controlled release
of bFGF which in turn promoted angiogenesis, and improved
cardiac function (116). Interestingly, the inflammatory response
quantified by CD45 staining at day 28 was higher in animals
injected with the polymer compared to saline. Near the polymer
injection site, there was a significant macrophage infiltration and
foreign body giant cells were also found, evidencing a chronic
inflammation response. Macrophages promote angiogenesis and
produce proangiogenic factors such as VEGF, IGF-1, and bFGF
(140). Hence, it is possible that the enhanced presence of
macrophages in polymer-treated animals has a beneficial effect
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by further improving the angiogenic response. However, time
points past 28 days are needed to elucidate if the inflammatory
response will be resolved appropriately to avoid detrimental
effects long-term.
ANTI-APOPTOTIC FACTORS
Cardiomyocytes apoptosis is responsible for most of the myocyte
death from the early stages of MI to the progression to HF.
It is in fact not only detected in the infarct area, but it
extends to the viable myocardium in remote non-infarcted
regions, characterizing all post-MI phases (61, 141, 142). Anti-
apoptotic therapeutic interventions therefore seem a potential
therapeutic strategy and could involve the use of injectable
hydrogels to deliver anti-apoptoticmolecules to attenuate the loss
of viable myocardium. Insulin-like Growth Factor 1 (IGF-1) and
Hepatocyte Growth Factor (HGF) can both activate the PI3K/Akt
pathway, enhancing cell survival, and reducing cardiomyocyte
apoptosis resulting in improved cardiac function (61, 143).
Examples of chemokines able to prevent myocyte apoptosis with
demonstrated effectiveness are Granulocyte colony-stimulating
factor (G-SCF) (144) and erythropoietin (EPO) (145, 146).
Insulin-like Growth Factor-1 (IGF-1)
IGF-1 is a 72 kDa polypeptide which plays key roles in cell
survival, proliferation, and differentiation via different signaling
pathways such as Ras-Raf mitogen active protein kinases and
phosphoinositide 3-kinase/Akt pathway (147). Buerke et al.
carried out the first study to show acute cardioprotective effects
of IGF-1, demonstrating that it reduced myocardial necrosis,
apoptosis, and neutrophil accumulation (148). Since then, the
beneficial effects of IGF-1 post-MI have been investigated by
several groups employing several strategies including IGF-1
myocardial overexpression (149, 150), gene therapy (151), and
systemic (152) and local administration (153). IGF-1 transgenic
overexpression not only activates survival signaling pathways
in the cardiomyocytes, but also mediates myocardial repair by
modulating the inflammatory response post-MI with decreased
expression of the pro-inflammatory cytokines IL-1β and IL-6
and increased expression of the anti-inflammatory IL-4 and IL-
10 compared to wild type mice (154). Moreover, cardiac-specific
overexpression of IGF-1 resulted in early accumulation of innate
immune cells at day 3 post-MI, with a reduction of inflammatory
myeloid populations (149). Similar trends were found when
IGF-1 was delivered through a single intravenous injection of
AAV9 containing a cardiac-restricted IGF-1 isoform (151). These
findings are supported by previous studies that identified anti-
inflammatory effects of IGF-1 in hyper-inflammatory conditions,
which were due to the induction of regulatory T cells (155, 156).
Addition of IGF-1 to cell therapy strategies enhances the
benefit of cell transplantation by promoting cell survival (157).
Recently, IGF-1 was delivered together with Bone Marrow Stem
Cells (BMSC) in a rabbit model of MI through biotinylated
self-assembly peptides and was able to suppress cardiomyocyte
apoptosis and promote the expression of cardiomyocyte-specific
proteins (158). These findings were confirmed for different
regenerative medicine applications such as cartilage repair (159),
peripheral vascular diseases (160) or acute kidney injury (161).
IGF-1 release with maintained bioactivity was shown in vitro
using an injectable, thermo-sensitive hydrogel composite capable
of gelling within 6 s (162). In this study, IGF-1 was also able
to increase the survival of mesenchymal stem cells (MSCs)
encapsulated in the gel, making the system an attractive strategy
for cardiac tissue engineering. Collectively these studies provide
evidence of how the combination of IGF-1 with therapeutic stem
cells delivery is a promising approach to increase the survival and
consequently the engraftment of transplanted cells. To date, there
are no studies using injectable biomaterials to deliver IGF-1 as a
single factor to the heart in vivo, but several reports of combined
delivery which will be covered in the next section.
Neuregulin-1β
Neuregulin-1β (NRG-1β), a member of the epidermal growth
factor (EGF) family, is another antiapoptotic factor that has
recently gained attention as a therapy for cardiovascular diseases.
The critical role of NRG-1β in both cardiac development
and maintenance of normal adult heart function is well-
established (163). NRG-1β receptor is expressed by human
cardiac ventricular fibroblasts and NRG-1β treatment of these
cells under stress has a pro-survival action (164). Moreover,
activation of the NRG-1β pathway induces the production
of angiopoietin-2 (Ang-2) and brain-derived neurotrophic
factor (BDNF), which have pro-angiogenic and pro-survival
effects, respectively (164). Systemic administration of NRG
has demonstrated efficacy in reducing fibrosis and improving
LV function in cardiomyopathy animal models (165–167),
leading to clinical trials employing daily infusion of high dose
recombinant NRG, which showed a modest improvement in
LV ejection fraction in comparison to placebo or low dose
administration (168). However, this approach involves daily
infusions and off-target exposure and therefore, novel clinically
translatable strategies are being investigated. As an example,
Cohen et al. developed a hydroxyethyl methacrylate (HEMA)-
based injectable hydrogel system to directly deliver NRG to
the myocardial border zone in a rat MI model, and showed
augmented cardiomyocyte mitotic activity, decreased apoptosis,
and greatly enhanced LV function without off-target exposure
(169). Other injectable systems that have been tested for NRG
delivery include PLGA-microparticles, which showed increased
ejection fraction and also improved angiogenesis when delivered
with a percutaneous intramyocardial injection in rat (170) and
porcine preclinical models of MI (171).
IMMUNOMODULATORY BIOACTIVE
MOLECULES
Due to the role of excessive inflammation in exacerbating
myocardial damage post-MI, a range of immunomodulatory
strategies have been attempted in clinical as well as in
experimental studies (55). Although current standard
pharmacotherapy post-MI has potent immunomodulatory
functions (172). systemic administration of these agents has
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so far shown little benefit, and adverse effects of systemic
immunomodulation limit their clinical translation.
Local delivery using hydrogels may be a promising
alternate strategy. Some naturally derived materials be
intrinsically anti-inflammatory. For example, chitosan
scavenges Reactive Oxygen Species (ROS) in vitro and in
vivo, which could explain the improved cardiac function
following chitosan hydrogel injection post-MI (173).
High molecular weight Hyaluronic Acid (HA) is another
material of natural origin with ROS-scavenging properties
(174, 175). Recently, also a fully synthetic hydrogel made
of polyglycerol sulfate-based PEG showed intrinsic anti-
inflammatory actions when tested in an in vitro model of
osteoarthritis (176). However, for most biomaterials, either
of natural or synthetic origin, loading of anti-inflammatory
therapeutics is necessary to modulate the inflammatory
cardiac microenvironment.
Anti-inflammatory cytokines share the same challenges for
in vivo delivery as other bioactive factors, most prominently
a short half-life. IL-10 is a pleiotropic cytokine with broad
immunoregulatory and anti-inflammatory activities (177). Daily
subcutaneous injection of IL-10 in a rat MI model resulted in
significantly decreased expression of pro-inflammatory cytokines
and reduced macrophages infiltration (178). Its half-life of
only 2.7–4.5 h (179), however, means that high doses and
repeated injections are needed, leading to increased risk of
side effects and high treatment cost. To overcome these issues,
an injectable coacervate hydrogel was recently implemented
for the delivery of IL-10 combined with bFGF in a mouse
model of acute MI (180). A single coacervate treatment of
500 ng each of bFGF and IL-10 led to long-term synergistic
benefit post-MI with ameliorated LV contractile function and
LV dilation. IL-2 and IL-19 have also proven beneficial against
post-MI remodeling when delivered exogenously (181), (182).
IL-2 is important for the survival of regulatory T cells,
whereas IL-19 inhibits proinflammatory macrophages, making
them promising candidates for incorporation into injectable
biomaterial systems.
Besides the delivery of exogenous anti-inflammatory factors,
inhibition of endogenous pro-inflammatory molecules may also
achieve immunomodulation. Tumor necrosis factor (TNF)-α
antagonism ameliorates ischemia/reperfusion injury (183) and
hydrogels delivering anti-TNF-α have been used for several
applications such as burns (184), wound healing (185) or
inflammatory bowel disease (IBD) (186). Therefore, a therapeutic
strategy using the same approach to salvage myocardial tissue
post-MI could be promising.
An emerging and translationally relevant therapeutic
approach to mitigate post-MI inflammation and remodeling
involves the localized augmentation of Tissue Inhibitor of
Metalloproteinases-3 (TIMP-3), a negative regulator of matrix
metalloproteinase (MMP) activity. The cause-effect relationship
between MMP induction and adverse LV remodeling has been
established through pharmacological MMP inhibition (187).
However, translation of systemic administration of MMP
inhibitors has encountered concerns around potential off-target
side effects when the delivery is not localized (188). Injectable
hydrogels represent an attractive alternate means of delivery
for TIMP-3. After the first proof of concept showing that
sustained regional delivery of TIMP-3 through a degradable
hyaluronic acid hydrogel can effectively block adverse LV
remodeling (189, 190), the hydrogel was recently modified
with an MMP-cleavable peptide (51). TIMP-3 release by this
system was tested in pigs following coronary artery ligation,
with promising results showing improved cardiac geometry
and function (51). In all of the above studies, the favorable
effects of TIMP-3 on post-MI remodeling are associated with an
attenuation of the local inflammatory process. TNF and TNF
receptor mRNA were increased in all post-MI groups but were
lower when delivering TIMP-3 in comparison to saline injection.
The same trend was shown for markers of macrophages
maturation and infiltration such as monocyte chemoattractant
protein-1 (MCP-1) and macrophage inflammatory protein-1α
(MIP-1α). Moreover, TIMP-3 release increased myofibroblast
density, an index of a stronger and more flexible scar (191).
This supports the notion that TIMP-3 improves LV geometry
through modifying biological mediators of the adverse post-MI
remodeling process (189).
Examples of anti-apoptotic and anti-inflammatory factors
delivered in animal models are summarized in Table 2.
TABLE 2 | Exemplar injectable biomaterials used for the in vivo delivery of anti-apoptotic and anti-inflammatory bioactive molecules in animal models of MI.
Biomaterial Growth
factor
Induced
mechanism
Animal
model
Time of
administration
Outcome References
Hydroxyethyl methacrylate
(HEMA)
Neuregulin-1β Anti-
apoptosis
Rat MI Immediately
after MI
Augmented cardiomyocytes mitotic activity and
decreased apoptosis. Improved cardiac
function with reduced left ventricular dilation
(169)
Poly(lactic-co-glycolic acid)
microparticles
Neuregulin-1β Anti-
apoptosis
Swine
ischemia/
reperfusion
1 week post
MI
Improvement in systolic and diastolic cardiac
function and decrease in transmural infarct
progression
(171)
Hyaluronic acid hydrogel TIMP-3 Anti-
inflammatory
Swine MI Immediately
after MI
Improved LV ejection fraction and reduced LV
dilation. Marked reduction in pro-inflammatory
cytokines
(189)
Metalloproteinase-
responsive hyaluronic acid
hydrogel
TIMP-3 Anti-
inflammatory
Swine MI Immediately
after MI
Reduced LV dilation and wall thinning.
Decrease in transcriptional profile for
pro-fibrotic pathways
(51)
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COMBINED DELIVERY OF MULTIPLE
GROWTH FACTORS
It is likely that a synergistic approach with simultaneous
administration of multiple factors may more accurately mimic
their natural mode of action and show more robust beneficial
effects. Further, incorporation of multiple agents in an optimized
ratio may allow for spatiotemporally controlled sequential
delivery of several bioactive factors with synergistic effects.
The PEG-fibrinogen hydrogel described above (109) was also
used for a dual delivery of VEGF and angiopoietin-1 (Ang-
1), another growth factor known to induce angiogenesis and
maturation of newly formed blood vessels both in vitro (192)
and in vivo (193, 194). The study demonstrated significant
improvement in cardiac function at 4 weeks in rats treated with
this combination of factors (195).
VEGF was also combined with HGF in a bioactive hydrogel
comprising PEG linked to a protease-degradable peptide to take
advantage of the high levels of proteases found in the ischemic
myocardium (196). This stimulus-responsive system triggers the
release of the encapsulated factors when remodeling occurs,
and it was tested in a rat model of MI (197). Interestingly,
when cardiac function was measured at day 7 post MI, only the
empty hydrogel showed a significant improvement in function,
as measured by fractional shortening. Conversely, at day 21 there
was a significant improvement in function only in the group that
received the hydrogel with the combination of factors (197). This
suggests that VEGF andHGF are not released fast enough to have
an effect in the acute phases, but they were efficient in inhibiting
fibrosis and inducing angiogenesis at later time points and only if
administered together.
Another common approach is to couple VEGF with other
factors such as platelet-derived growth factors (PDGF-BB) that
support the stability and the connectivity of new vessels by
recruiting smooth muscle cells (198). PDGF signaling plays
an essential role in cardiovascular development (199) and
in both mouse and humans the PDGF family consists of
four ligands, PGDF-A-D. However, only PDGF-A and PDGF-
B are capable of forming functional heterodimers (199) and
have been shown to protect cardiomyocytes from apoptosis
and improving contractile function of an engineered heart
tissue (200). VEGF165 and PDGF-BB have been co-delivered
through an alginate hydrogel, leading to improvements in
cardiac function more than with each factor separately (198).
Moreover, endothelial cells promote cardiomyocytes survival
via PDGF signaling (201). A recent proangiogenic combination
strategy involved the delivery of Stromal Derived Factor-1 (SDF-
1) and an angiogenic small tetrapeptide (Ac-SDKP) for bone
marrow stem cell recruitment and angiogenesis, respectively
(36). It showed how dual therapeutic factors can provide
an injectable 3D microenvironment for recruiting MSCs into
the ischemic area and, at the same time, play a role for
stimulating neoangiogenesis.
IGF-1 has been coupled with several other factors for dual
delivery and tested in vivo in MI models. Sequential delivery
of regenerative factors is thought to be more effective than
simultaneous delivery because it mimics the naturally-occurring
healing phases (47). Alginate hydrogels were used for the
sequential delivery of IGF-1 and HGF (202) in a rat model of
MI. To increase the local potency of the factors at the infarct
exploiting a localized stimulus, the delivery was carried out
in a partially-crosslinked alginate solution, previously shown
to undergo gelation in response to the high concentration of
calcium ions that characterize the ischemic myocardium. The
alginate hydrogel formed in situ, creating a local reservoir for
the factors and providing an additional barrier against protein
diffusion (202). The sequential release was achieved by varying
the initial loading concentrations of the two factors. The study
showed attenuated infarct expansion and diminished fibrosis,
together with enhanced angiogenesis at the infarct site following
dual delivery.
Furthermore, dual delivery of IGF-1 and VEGF was
implemented in a study using injectable gelatin microspheres
in a rat MI model (203). This showed how the neoangiogenesis
promoted by VEGF can potentiate the anti-apoptotic actions of
IGF-1, resulting in a marked reduction of infarct size associated
with improved cardiac function. Nelson et al. encapsulated both
IGF-1 and bFGF in a thermo-responsive synthetic hydrogel made
of Poly(NIPAAm-co-HEMA-coMAPLA) (47) and previously
described (204). Interestingly, cardiac function in the hydrogel-
treated animals was improved at the 16 weeks timepoint
compared to saline injection. However, both functional and
histological evaluation showed no further benefit with the
encapsulation of the factors compared to the empty gel (47).
This could be due to the late time point chosen for gel injection
in this study (2 weeks post-MI), since IGF-1 is more effective
in preventing apoptosis in the early phases after an infarction
(205). The material used in this study had a slow in vivo
degradation rate (4–5 month); while the gold-standard for in situ
degradation timing is still debated, a material designed to provide
mechanical support should have a degradation time longer than
2 months (47, 206). The improvement shown in this study,
regardless of factors incorporation, could then be explained by
the long degradation rate, which allowed a slow shift of load-
bearing responsibilities to the newly formed tissue. Moreover, a
slow-degrading material remains in the tissue for enough time
to support cell recruitment at the injection site, contributing
to the overall success of the approach. Notably, macrophage
infiltration to the site of injury was still significant 16 weeks
after hydrogel injection (47). The majority of these cells stained
positive for CD163, a scavenger receptor specifically expressed
on the surface of activated anti-inflammatory macrophages and
monocytes (207).
A combination of IGF-1 and bFGF increased ejection fraction
and reduced pathological hypertrophy when delivered through
a pH-switchable hydrogel [49] in a porcine model of chronic
MI with catheter-based state of the art technology (208). These
results are particularly promising not only for the use of a
highly translatable delivery system in a large animal model
but also due to the time of injection (4 weeks post-MI)
which has clinical relevance for chronic MI in patients. A
synergistic effect of stromal-derived factor-1 (SDF-1) and the
small angiogenic tetra peptide Ac-SDKP was demonstrated
in a rat chronic MI model using an injectable biomimetic
Frontiers in Cardiovascular Medicine | www.frontiersin.org 11 March 2019 | Volume 6 | Article 26
Ferrini et al. Bioengineering Strategies for Immunomodulation
hyaluronic acid hydrogel for the dual delivery to the heart
(36). SDF-1 increases cardiomyocyte survival in the infarct
zone and promotes stem cells mobilization and stabilization
(209, 210). Examples of dual delivery approaches tested in
vivo in animal models are summarized in Table 3. Recently,
Awada et al. demonstrated that proper spatial and temporal
cues from proteins are essential by using for the first time a
combination of three complementary factors, TIMP-3, bFGF, and
SDF-1α embedded in heparin-based coacervates for sustained
release regulated in a timely fashion (211). TIMP-3 reduced
ECM degradation early after MI, while bFGF and SDF-1α
triggered a robust angiogenic process and progenitor cell
recruitment over an 8 weeks period (211). A recent trend
involves the delivery of a cocktail of stem cell-derived bioactive
molecules known as secretome, which includes cytokines, growth
factors, and exosomes. A nanocomposite injectable hydrogel
loaded with secretome from human adipose-derived stem
cell has been tested for its regenerative potential in vitro
and in vivo in an acute MI rat model (212). The injection
of the secretome-loaded hydrogel in the peri-infarct area
provided cardioprotection promoting increased angiogenesis
and reduction of cardiac remodeling (212). In summary, a
successful outcome of this approach is dependent upon the
choice of the right growth factors, in the right combination and
at the right concentration.
A different strategy involves the use of injectable hydrogel
for the delivery of RNAi molecules such as siRNA, miRNA,
and shRNA to boost regeneration. RNAi molecules have a
short half-life and are rapidly cleared if delivered systemically
(213). Therefore, as bioactive factors, they could highly benefit
from a localized and controlled delivery, as reviewed in Wang
and Burdick (213). Although the field is still in its infancy,
some recent applications for cardiac repair have already shown
promising results (214–216).
TABLE 3 | Exemplar injectable biomaterials used for the in vivo combined delivery of multiple bioactive factors in animal models of MI.
Biomaterial Growth
factor
Induced mechanism Animal
model
Time of
administration
Outcome References
PEG-fibrinogen
hydrogel
VEGF +
Ang-1
Pro-angiogenesis +
stabilization of newly
formed vessels
Rat MI Immediately
after MI
Improvement in EF and neoangiogenesis,
more significant with dual delivery
compared to single factor delivery.
(195)
Protease-responsive
PEG-based hydrogel
VEGF + HGF Pro-angiogenesis Rat ischemia/
reperfusion
Immediately
after injury
Significant increase in angiogenesis, stem
cell recruitment, inhibition of collagen
deposition and decrease in fibrosis with
dual delivery.
(197)
Alginate hydrogel VEGF +
PDGF
Pro-angiogenesis +
recruitment of smooth
muscle cells to support
new vessels
Rat MI Immediately
after MI
Higher density of mature vessels and
improvement in cardiac function.
(198)
Biomimetic hyaluronic
acid hydrogel
SDF-1 +
Ac-SDKP
Pro-angiogenic + bone
marrow stem cell
recruitment
Rat MI Immediately
after MI
Improved LV function, increased
angiogenesis, and wall thickness.
(36)
Affinity-binding alginate
microbeads
IGF-1 + HGF Anti-apoptosis +
pro-angiogenesis
Rat MI Immediately
after MI
Attenuation of infarct expansion and
reduced scar fibrosis.
(202)
Gelatin hydrogel
microspheres
IGF-1 +
VEGF
Anti-apoptosis +
pro-angiogenesis
Rat MI Immediately
after MI
Decreased apoptosis and inflammation.
Significant neoangiogenesis. Marked
reduction of infarct size and improved
cardiac function.
(203)
Thermo-responsive
Poly(NIPAAm-co-
HEMA-coMAPLA)
hydrogel
IGF-1 + bFGF Anti-apoptosis +
pro-angiogenesis
Rat MI 2 weeks after
MI
Improvement in cardiac function with
empty gel. No added benefit of GF
addition.
(47)
pH-switchable
supramolecular UPy
hydrogel
IGF-1 + bFGF Anti-apoptosis +
pro-angiogenesis
Porcine
chronic MI
4 weeks post
MI
Reduced pathological hypertrophy and
increased capillarization.
(208)
PLGA and PEG-PLGA
microparticles
NRG-1β +
bFGF
Anti-apoptosis +
pro-angiogenesis
Rat MI 4 days post
MI
Enhanced EF and neoangiogenesis. No
difference between PLGA and PEG-PLGA
system.
(170)
Heparin-based
coacervate hydrogel
IL-10 + bFGF Anti-inflammatory +
pro-angiogenesis
Mouse MI Immediately
after MI
Improvement in long-term LV contractile
function and ameliorated LV dilation.
Enhanced revascularization of the
infarcted area.
(180)
Fibrin coacervate gel TIMP-3 +
bFGF +
SDF-1α
Anti-inflammatory +
pro-angiogenic +
progenitor cells
recruitment
Rat MI Immediately
after MI
Reduced ventricular dilation, inflammation
and ECM degradation. Improved cardiac
function.
(211)
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CHALLENGES AND CLINICAL
PERSPECTIVES
The physical and biological properties of the injected material,
together with timing and location of injections and distribution
of the hydrogel in the cardiac wall are some of the parameters that
may contribute to a successful post-MI treatment.
A consensus should be reached on what is considered a
successful outcome for an injectable biomaterial study and what
is the best parameter, or parameter combination, to focus on.
In the studies presented in this review, wall thickness, fractional
shortening, LV volumes, ejection fraction, infarct size, and
vascularization of the infarct have all been considered. In the
clinical setting, End Systolic Volume (ESV) has been shown to
be the best predictor of survival and re-hospitalization (217).
Specific considerations for myocardial applications are:
Immunomodulatory Aspects
Timing and location are crucial for the control of inflammation
in the damaged heart. As we gain a more detailed understanding
of the shifting post-MI immune response, an equally
dynamic therapeutic protocol would engage a spectrum
of immunomodulatory interventions during the post-MI
period. Targeted delivery of these therapeutic agents is equally
critical: although clinical trials involving immunomodulation
use broad immunosuppressive protocols that have proven
partially successful, a more localized dispatch of commonly
used immunosuppressive treatments in the heart may greatly
improve their immunomodulatory efficacy while minimizing
systemic adverse effects. While production of engineered
materials has historically been focused on maximizing their
bioinert properties, recent studies reflect a shift toward active
biomaterials that elicit a controlled inflammatory response as
described above. Although several considerations are necessary
when designing an injectable hydrogel, alginate hydrogels
have already been used in clinical settings (218). However,
one disadvantage of these materials is that they might retain
some surface antigens capable to elicit an immune response.
Conversely, synthetic materials are designed with defined
chemical compositions that does not elicit a foreign body
response, but often require functionalization with appropriate
bioactive molecules to support cell attachment and survival. In
the future, hydrogels with natural-synthetic hybrid compositions
may allowmore precise delivery of immunomodulatory biologics
at the right place and time.
Effects on the Cardiac Conduction System
A significant concern when injecting a hydrogel into the
myocardial wall is its possible effect on the cardiac conduction
system. This is particularly important for patients eligible for
a biomaterial therapy who may already have an increased risk
of developing ventricular arrhythmias (219). Suarez et al. used
optical mapping to study the effect of interstitial spread with
PEG-based hydrogels in rats and did not observe changes
to action potential propagation with high spreading materials
characterized by slow gelation times (219). Conversely, materials
with a quicker gelation time that form a bolus could potentially
be a substrate for arrhythmias (219). This interesting study
about a material design criterion that is often overlooked
needs to be repeated in large animal models and with other
biomaterials to provide better foundations for safer clinical use
of injectable hydrogels.
Biodegradability
Degradation time of a hydrogel is a key parameter but data
about biodegradability in vivo are still lacking. For myocardial
tissue engineering, a material is considered biodegradable if
degradation occurs through hydrolytic or enzymatic activity
in vivo and if the degradation products comply with the
requirements of both biodegradability and biocompatibility (29).
In general, a material should persist long enough to have
the desired effect but not longer than necessary to affect the
repair process. Therefore, biomaterials designed for delivery of
bioactive factors should persist in vivo for at least 1 week since
most of the cell death occurs within the first few days after
MI and should be fully degraded in 6–8 weeks. Materials of
natural origin such as ECM-derived materials provide the correct
composition to allow cell adhesion and survival and are degraded
within days to weeks by enzymes produced by the cells into
biodegradable and biocompatible products. Given the extensive
research conducted in small animal models, the next step for
a better in vivo characterization of biodegradability will require
studies in large animal models, and longer-term follow-up to
delineate the mechanisms in which these materials act, both
biologically and mechanically.
CONCLUSIONS
Numerous preclinical studies on hydrogel-mediated delivery of
bioactive factors to the heart have shown therapeutic benefit
in terms of global cardiac parameters such as improved or
maintained left ventricular geometry and ejection fraction. It
is now widely acknowledged that the mechanism of action of
successful cell therapy for cardiac repair occurs via paracrine
signaling (220). Amplifying this therapeutic approach by local
hydrogel-mediated delivery of salutary factors to improve cell
survival, vascularisation and prevent excessive inflammation
represents a promising avenue that could accelerate the
development of novel treatment for MI and HF. The field of
controlled-release systems through biomaterials is still in its
infancy but offers significant potential to modulate immune
response, modulate inflammation, and minimize infarct scar,
promote angiogenesis to prevent cell death, and provide
the necessary extracellular milieu for constructive cardiac
remodeling after injury.
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